TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $575

Benzinga · 1d ago
TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $550 to $575.